Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
4
×
boston blog main
boston top stories
life sciences
national blog main
biotech
national top stories
drugs
editas medicine
gene editing
agios therapeutics
akcea therapeutics
allergan
alnylam pharmaceuticals
base editing
biopharma
branden moriarty
broad institute
cas13
clinical trials
crispr
crispr therapeutics
crispr-cas9
cynthia collins
david liu
deals
dna
duchenne
editor
editr
enzyme
europe blog main
europe top stories
european medicines agency
fda
feng zhang
harvard pilgrim health care
harvard university
hereditary transthyretin amyloidosis
inotersen
What
gene
4
×
medicine
4
×
crispr
editas
editing
fda
rna
therapeutics
therapy
allergan
alnylam
approval
approves
beam
betting
billion
biopharma
blessing
bosley
cas
cells
ceo
check
clinical
cusp
deal
depart
drug
duchenne
editor
ema
employ
europe
experimental
follows
founders
gotten
harmful
harvard
historic
Language
unset
Current search:
gene
×
boston
×
medicine
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M